0

Oral and Inhaled p38 MAPK Inhibitors: Effects on Inhaled LPS Challenge in Healthy Subjects

Dave Singh, Leonard Siew, Jared Christensen, Jonathan Plumb, Graham W Clarke, Steve Greenaway, Christelle Perros-Huguet, Nick Clarke, Iain Kilty, Lisa Tan

Eur J Clin Pharmacol. 2015 Oct;71(10):1175-84.

PMID: 26265232

Abstract:

Background:
Inhaled LPS causes neutrophilic airway inflammation in healthy subjects. We compared the effects of p38 MAPK inhibitors and fluticasone propionate on the LPS response.
Methods:
Three randomised, double-blind, placebo-controlled, single dose crossover studies were performed. Active treatments were the oral p38 MAPK inhibitor PH-797804 30 mg (study 1), PH-797804 30 mg and the inhaled p38 MAPK inhibitor PF-03715455 20 mg (study 2) and inhaled fluticasone propionate 500 μg (study 3). The primary endpoint was sputum neutrophil percentage.
Results:
Sputum neutrophil percentage post-LPS challenge was significantly inhibited (15.1 and 15.3% reduction) by PH-797804 compared to placebo in studies 1 and 2 (p = 0.0096 and 0.0001, respectively), and by PF-03715455 (8.0% reduction, p = 0.031); fluticasone propionate had no effect. PH-797804 significantly inhibited the increase in inflammatory mediators (IL-6, MCP-1, MIP1β and CC16) in sputum supernatant, while PF-03715455 had no effect. PH-797804 and PF-03715455 both inhibited IL-6, MCP-1, MIP1β, CC16 and CRP levels in plasma, with PH-797804 having greater effects. Fluticasone propionate had no effect on sputum supernatant or plasma biomarkers.
Conclusions:
PH-797804 had the greatest impact on neutrophilic airway inflammation. Oral administration of p38 MAPK inhibitors may optimise pulmonary anti-inflammatory effects.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP586379660 PH-797804 PH-797804 586379-66-0 Price
qrcode